Ankur Jindal1*, Rakesh K Jagdish1 and Aditi Gupta2
1Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
2Visiting Consultant Dermatologist, Institute of Liver and Biliary Sciences, New Delhi, India
*Corresponding Author: Ankur Jindal, Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Received: August 28, 2020; Published: September 30, 2020
The coronavirus disease 2019 (COVID-19) was first notify to WHO on December 2019 by china after its eruption in Wuhan, subsequently now it has been noticed globally and WHO Declares it as pandemic on 11-3-2020. Respiratory manifestations are predominant feature of COVID-19, but in severe illness and critical patients multi-organ involvement occurs and results in dismal prognosis. Liver patients are also at great risk of worsening of underlying compensated condition and can develop acute decompensation or exacerbation of liver disease with high morbidity and mortality especially in immunosuppressed state due to advanced liver diseases and some patients on immunosuppressive drugs; e.g. autoimmune liver disease and post liver transplantation. This mini review is about the brief summary of the impact of COVID19 infection on patients of liver diseases and management of COVID in liver patients.
Keywords: Liver Cirrhosis; COVID-19; SARS-COV2; Management
Citation: Ankur Jindal., et al. “COVID-19 and Liver Disease". Acta Scientific Gastrointestinal Disorders 3.10 (2020): 20-27.
Copyright: © 2020 Ankur Jindal., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.